Development of improved PPARβ/δ inhibitors
Philipp M Toth1, Simone Naruhn, Veronika F S Pape
1Institut für Pharmazeutische Chemie, Philipps-Universität Marburg, Marburg, Germany.
Chemmedchem
|October 26, 2011
Summary
Researchers developed novel PPARβ/δ inhibitors with enhanced binding affinity. These new compounds, derived from GSK0660, offer improved tools for studying peroxisome proliferator-activated receptor beta/delta functions.
Area of Science:
- Medicinal Chemistry
- Molecular Pharmacology
- Biochemistry
Background:
- Peroxisome proliferator-activated receptor beta/delta (PPARβ/δ) is a nuclear receptor involved in various physiological processes.
- Selective PPARβ/δ inhibitory ligands are crucial for dissecting its specific functions.
- GSK0660 is the first described selective PPARβ/δ inhibitory ligand.
Purpose of the Study:
- To design and synthesize novel PPARβ/δ inhibitory ligands with improved binding affinity.
- To establish preliminary structure-activity relationships (SAR) for PPARβ/δ inhibitors.
- To develop valuable tools for further research into PPARβ/δ biology.
Main Methods:
- Chemical synthesis of modified compounds based on the GSK0660 scaffold.
- Evaluation of binding affinity to the PPARβ/δ ligand binding domain.
- Cell-based assays to confirm subtype-specific inhibition of PPARβ/δ.
Main Results:
- Replacement of the 4'-aminophenyl group with n-alkyl chains (e.g., n-butyl, iso-pentyl) enhanced binding affinity.
- Novel compounds exhibited activity in the low nanomolar range, up to tenfold higher affinity than GSK0660.
- Subtype-specific inhibition of PPARβ/δ was confirmed in cellular assays.
Conclusions:
- The newly synthesized compounds represent a significant advancement in PPARβ/δ inhibitory ligand development.
- These potent and selective inhibitors are valuable tools for investigating PPARβ/δ roles in biological systems.
- Further exploration of PPARβ/δ functions can be facilitated by these optimized chemical probes.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:31Transducer Mechanism: Nuclear Receptors
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:15G Protein-coupled Receptors
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...